Key result
Right anterior thoracotomy AVR achieves ~1% 30-day mortality with low sternotomy conversion.
Why the study?
Published experience with right anterior thoracotomy aortic valve replacement (RAT-AVR) largely reflects late-experience series from specialised centres, and data describing operative technique and early outcomes during real-world adoption remain limited.
Is right anterior thoracotomy aortic valve replacement (RAT-AVR) safe, feasible, and efficient during real-world adoption in patients undergoing isolated aortic valve replacement?
Cohort (n=156)
Yes
Is right anterior thoracotomy aortic valve replacement (RAT-AVR) safe, feasible, and efficient during real-world adoption in patients undergoing isolated aortic valve replacement?
This single-surgeon consecutive series demonstrates that minimally invasive right anterior thoracotomy aortic valve replacement (RAT-AVR) can be safely adopted into routine clinical practice with low 30-day mortality (1.3%), low conversion rates (1%), and significantly improved operative times after an initial 50-case learning curve.
Answers are grounded in this paper and cite their sources.
Supports RAT-AVR feasibility with low mortality; leaves open randomized comparisons versus sternotomy.
Background: Right anterior thoracotomy aortic valve replacement (RAT-AVR) is an established minimally invasive alternative to conventional sternotomy, but published experience largely reflects late-experience series from specialised centres. Data describing operative technique and early outcomes during real-world adoption remain limited. Methods: We describe our operative technique and early outcomes in 156 consecutive intended isolated RAT-AVR procedures performed by a single surgeon between January 2015 and November 2025. Operative times were compared between the first 50 and subsequent 106 cases and assessed using cumulative sum analysis. Results: Median age was 70 years and median EuroSCORE II was 1.00% [IQR 0.71–1.56]. Peripheral cannulation was used in most cases, with central cannulation employed selectively. Mechanical and biological prostheses spanning 19–29 mm were implanted, demonstrating that prosthesis choice was not restricted in this cohort. Median cardiopulmonary bypass and cross-clamp times were 109 and 79 min, respectively. Both were shorter after the first 50 cases (120.5 versus 106.0 min, p = 0.003; 85.5 versus 77.0 min, p = 0.048). Conversion to sternotomy occurred in two patients, both of whom survived to discharge and 30 days. Thirty-day mortality was 2/156 (1.3%). Conclusions: This consecutive single-surgeon experience supports the feasibility and early safety of RAT-AVR in selected patients, with operative efficiency improving during adoption. RAT-AVR represents a pragmatic minimally invasive option for isolated surgical aortic valve replacement.
No takes yet. Share an insight, caveat, or question.
Shell et al. (2026) conducted a cohort in Severe aortic valve stenosis or regurgitation requiring isolated aortic valve replacement (n=156). Right anterior thoracotomy aortic valve replacement (RAT-AVR) was evaluated on 30-day mortality. Right anterior thoracotomy aortic valve replacement resulted in a 1.3% 30-day mortality rate and a 1% sternotomy conversion rate across 156 consecutive patients.
Synapse has enriched 10 related papers. Consider them for comparative context: